HomeCompareAGE vs GBDC

AGE vs GBDC: Dividend Comparison 2026

AGE yields 18.02% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.79M in total portfolio value· pulled ahead in Year 2
10 years
AGE
AGE
● Live price
18.02%
Share price
$11.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.6K
Annual income
$5,421.64
Full AGE calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — AGE vs GBDC

📍 GBDC pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGEGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGE + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGE pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGE
Annual income on $10K today (after 15% tax)
$1,531.53/yr
After 10yr DRIP, annual income (after tax)
$4,608.39/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,978,515.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGE + GBDC for your $10,000?

AGE: 50%GBDC: 50%
100% GBDC50/50100% AGE
Portfolio after 10yr
$10.46M
Annual income
$8,228,077.74/yr
Blended yield
78.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

AGE
No analyst data
Altman Z
-20.5
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGE buys
0
GBDC buys
0
No recent congressional trades found for AGE or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGEGBDC
Forward yield18.02%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$64.6K$20.85M
Annual income after 10y$5,421.64$16,450,733.83
Total dividends collected$34.8K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: AGE vs GBDC ($10,000, DRIP)

YearAGE PortfolioAGE Income/yrGBDC PortfolioGBDC Income/yrGap
1$12,502$1,801.80$12,492$1,791.70+$10.00AGE
2← crossover$15,482$2,105.21$16,527$3,160.58$1.0KGBDC
3$19,002$2,436.52$23,588$5,904.90$4.6KGBDC
4$23,127$2,794.89$37,141$11,901.65$14.0KGBDC
5$27,925$3,179.07$66,205$26,463.38$38.3KGBDC
6$33,468$3,587.47$137,452$66,612.65$104.0KGBDC
7$39,829$4,018.19$342,372$195,298.53$302.5KGBDC
8$47,086$4,469.06$1,053,292$686,954.33$1.01MGBDC
9$55,319$4,937.71$4,111,439$2,984,416.95$4.06MGBDC
10$64,613$5,421.64$20,849,974$16,450,733.83$20.79MGBDC

AGE vs GBDC: Complete Analysis 2026

AGEStock

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.

Full AGE Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this AGE vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGE vs SCHDAGE vs JEPIAGE vs OAGE vs KOAGE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.